BPC-157 & TB-500

BPC-157 & TB-500 Blend (5mg/5mg) — Research Peptide

This combination research peptide provides BPC-157 and TB-500 (Thymosin Beta-4 fragment) in a 5mg/5mg blend per vial. The research rationale for combining these two compounds lies in their complementary and non-overlapping mechanisms of action — BPC-157 operating primarily through VEGFR2-angiogenic and EGR1-collagen pathways, while TB-500 (Tβ4) functions as an actin-sequestering protein promoting cell migration and satellite cell activation.

Research Rationale for Combination

BPC-157 and Thymosin Beta-4 have distinct biological targets that research suggests may act synergistically in tissue repair models. BPC-157 drives vascular supply to injury sites through angiogenesis, while Tβ4 facilitates the migration of repair-competent cells (fibroblasts, myoblasts, endothelial progenitors) into the repair zone via its actin regulatory function. Multiple research groups have studied the combination in musculoskeletal injury models, with published data suggesting additive effects on wound closure and collagen organisation versus either compound used independently.

Component Mechanisms

BPC-157 (5mg): VEGFR2/Akt/eNOS angiogenesis, EGR1-driven collagen expression, cytoprotection, NO pathway modulation.

TB-500/Tβ4 fragment (5mg): G-actin sequestration, cell migration facilitation, integrin-linked kinase (ILK) activation, cardiac and skeletal muscle progenitor mobilisation.

Product Specifications

• Peptides: BPC-157 (5mg) + TB-500/Thymosin Beta-4 fragment (5mg)
• Format: Co-lyophilised powder blend, bulk box of 10 vials
• Purity: Each component ≥98% verified by Janoshik HPLC
• Testing: Full Janoshik COA — purity, sterility, endotoxin, heavy metals
• Storage: -20°C. Stable 24 months lyophilised.

For laboratory research use only. Not for human therapeutic use.